UBS Maintains Neutral on PROCEPT BioRobotics, Raises Price Target to $21
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
UBS analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral and raises the price target from $20 to $21.
UBS analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral and raises the price target from $20 to $21.